Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial

Heart. 2009 May;95(9):704-8. doi: 10.1136/hrt.2008.154054. Epub 2009 Jan 28.


Objective: To determine the efficacy of statin treatment in atrial fibrillation (AF) prevention in women.

Design: Cohort study using data obtained in the Heart and Estrogen/Progestin Replacement Study (HERS).

Setting: Secondary analysis of a multicentre, randomised controlled clinical trial.

Patients: 2673 Postmenopausal women with coronary disease.

Main outcome measures: AF prevalence at baseline and incident AF over a mean follow-up of 4.1 years.

Results: 88 Women with AF were identified: 29 at baseline and 59 during follow-up. Women with AF were significantly less likely to be taking a statin at study enrollment than those without AF (22% vs 37%, p = 0.003). Baseline statin use was associated with a 65% lower odds of having AF at baseline after controlling for age, race, history of myocardial infarction or revascularisation and history of heart failure (odds ratio 0.35, 95% confidence interval (CI) 0.13 to 0.93, p = 0.04). The risk of developing AF during the study among those free from AF at baseline, adjusted for the same covariates, was 55% less for those receiving statin treatment (hazard ratio 0.45, 95% CI 0.26 to 0.78, p = 0.004).

Conclusions: Statin treatment is associated with a lower prevalence and incidence of AF after adjustment for potential confounders in postmenopausal women with coronary disease.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / prevention & control*
  • Cohort Studies
  • Coronary Disease / complications*
  • Estrogen Replacement Therapy
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Postmenopause
  • Prevalence


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors